SCHEMBL4835675

SCHEMBL4835675

N#Cc1c(N)sc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.46
IDO1 P14902 4/20 0.44
GPR3 P46089 1/20 0.44
ALDH1A1 P00352 8/20 0.42
MAPT P10636 5/20 0.42
KDM4E B2RXH2 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
GAA P10253 3/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
HPGD P15428 3/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALOX15 P16050 4/20 0.38
HSD17B10 Q99714 4/20 0.38
POLB P06746 2/20 0.38
CASP1 P29466 2/20 0.38
BRCA1 P38398 2/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9000153 0.85 IDO1 (0.44) GRM6IDO1GPR3ALDH1A1MAPT
SCHEMBL31388718 0.78 GPR3 (0.46) GRM6GPR3ALDH1A1MAPTKDM4E
SCHEMBL29915175 0.76 GPR3 (0.44) GPR3ALDH1A1MAPTKDM4EMEN1
SCHEMBL11331315 0.76 LIMK1 (0.46) GRM6IDO1GPR3ALDH1A1MAPT
SCHEMBL23087421 0.76 GPR3 (0.44) GPR3ALDH1A1MAPTKDM4EMEN1
SCHEMBL25337040 0.76 GPR3 (0.44) IDO1GPR3ALDH1A1MAPTKDM4E
SCHEMBL1514430 0.76 GPR3 (0.44) GRM6GPR3ALDH1A1MAPTKDM4E
SCHEMBL12750484 0.76 GPR3 (0.44) GRM6GPR3ALDH1A1MAPTKDM4E
SCHEMBL6998140 0.74 CYP2A6 (0.40) GRM6IDO1ALDH1A1MAPTKDM4E
SCHEMBL7000794 0.74 USP20 (0.39) GRM6IDO1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026903-A1 IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2025-02-06 WO claimed
EP-4719369-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING Celloram, Inc. (US) 2026-04-08 EP disclosed
EP-4665719-A1 SMALL MOLECULE TREATMENT OF FATTY LIVER DISEASE AND HCC ScandiEdge Therapeutics AB (SE) 2025-12-24 EP disclosed
EP-4596551-A1 COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY Trasveda Ltd. (KY) 2025-08-06 EP disclosed
WO-2025077770-A1 FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR 成都海博为药业有限公司 2025-04-17 WO disclosed
WO-2025051242-A1 RAS INHIBITOR 泰励生物科技(上海)有限公司 2025-03-13 WO disclosed
CN-119591588-A RAS inhibitors 泰励生物科技(上海)有限公司 2025-03-11 CN disclosed
CN-119546309-A Methods of treatment comprising KRAS G12C inhibitors and AURORA a inhibitors 伊莱利利公司 2025-02-28 CN disclosed
WO-2025026903-A1 IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2025-02-06 WO disclosed
WO-2024254161-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING CELLORAM INC. (US) 2024-12-12 WO disclosed
US-6723848-B2 TETRAHYDROBENZOFURAN OR TETRAHYDROBENZOTHIOPHEN OR TETRAHDYROBENZOPYRROLE COMPOUNDS CAN BE AROMATIZED WITH A HYDROGENATION CATALYST IN PRESENCE OF A HYDROGEN ACCEPTOR, DEACYLATION OF AMINO GROUP BY ADDITION OF AN AMINE GROUP MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2004-04-20 US disclosed
WO-2004014895-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed
WO-2003104219-A1 NF-KB INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 WO disclosed
WO-2003082877-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS ELI LILLY AND COMPANY (US) 2003-10-09 WO disclosed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-20030078422-A1 Method for producing benzo annelated heterocycles MERCK PATENT GMBH (DE) 2003-04-24 US disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT GRM6 347/4885IDO1 1366/4885GPR3 3174/4885
US-20030078422-A1 Method for producing benzo annelated heterocycles NAT1, AFF1, SAT1 GRM6 2061/4885IDO1 238/4885GPR3 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.